Partner Headlines - GSK

  1. BP: Asset Sales, New Projects Fuel Its 6.7% Dividend Yield

    TalkMarkets
  2. GlaxoSmithKline: Robust Pipeline Supports its 5.5% Dividend Yield

    TalkMarkets
  3. GSK: Robust Pipeline Supports its 5.5% Dividend Yield

    TalkMarkets
  4. Better Than The Maestro

    TalkMarkets
  5. 6 Worthy Dividend Stocks Down 10% Or More

    TalkMarkets
  6. Musings And Global Markets

    TalkMarkets
  7. Trump Triumphs

    TalkMarkets
  8. Pharmaceutical Stocks Surge After Republican Victory

    TalkMarkets
  9. Week In Review: China Healthcare And Pharma Deals

    TalkMarkets
  10. Global Roundup: Roche, Vale, Novo Nordisk, Teva, Benitec Et Al ...

    TalkMarkets
  11. Week In Review: China Resources Pharma To Price $2 Billion Hong ...

    TalkMarkets
  12. Seven Sources of Competitive Advantage

    TalkMarkets
  13. The Internet Of Medical Things: 6 Stocks In Focus

    TalkMarkets
  14. Alphabet-Glaxo Joint Venture Targets 'Bioelectronics'

    Investors Business Daily
  15. Veeva Is Key Partner In Big Pharma's Race Against The Clock

    Investors Business Daily
  16. Stock Futures Up, Gaining Strength; Apple Hauls Techs Higher

    Investors Business Daily
  17. Lilly, J&J, Novo Battle For Diabetes Market Heats Up; FDA Rulings ...

    Investors Business Daily
  18. Getting to Know VBI Vaccines

    GuruFocus
  19. Brandes Makes a Variety of Reductions in 4th Quarter

    GuruFocus
  20. Stock Futures Up As Oil Behaves; Syngenta Up On ChemChina Deal

    IBD
  21. EXCLUSIVE: Inovio Plans On Producing Zika Vaccine By Q3 2016, ...

    Benzinga
  22. Benzinga's M&A Chatter for Thursday January 28, 2015

    Benzinga
  23. 10 Fund Managers Are Totally Wrong on GlaxoSmithKline

    GuruFocus
  24. Stocks Bring High Dividend Yields to HOTCHKIS & WILEY

    GuruFocus
  25. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  26. Dynavax Hepatitis B Vaccine Beats Glaxo's In Trial

    IBD
  27. Jeff Auxier's Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  28. Cisco Systems, Microsoft and Intel Bring High Dividend Yields ...

    GuruFocus
  29. The 5 Top-Performing Big-Cap Drug Stocks Of 2015

    IBD
  30. High Dividend Yield Ratios Are Hallmarks of Many Dodge & Cox ...

    GuruFocus
  31. Glaxo's ViiV Acquiring Bristol-Myers' HIV Candidates

    IBD
  32. John Rogers' Holdings Trading Below Peter Lynch Earnings Line

    GuruFocus
  33. 3 Global Investment Ideas From Gurus

    GuruFocus
  34. Relypsa Stock Jumps On Buyout Rumors

    IBD
  35. Skin Disease Drug Costs Jump

    IBD
  36. Valeant, Glaxo, Novartis Skin Drug Prices Have Soared

    IBD
  37. Dodge & Cox Sells Most of Stakes in Chevron, GlaxoSmithKline

    GuruFocus
  38. 3 Investment Ideas of Ariel Investment's Rupal Bhansali

    GuruFocus
  39. Pfizer to Create a New Pharmaceutical Colossus

    GuruFocus
  40. GlaxoSmithKline

    IBD
  41. Gilead Beats Q3 Estimates As HIV Franchise Shines

    IBD
  42. ISIS Pharmaceuticals Earns $5M from GSK for Initiation of Phase ...

    Benzinga
  43. Benzinga's Top Upgrades

    Benzinga
  44. IBM, Schlumberger PTs Lowered; Valeant Downgraded

    IBD
  45. GlaxoSmithKline Has a High (and Dangerous) Dividend Yield

    GuruFocus
  46. Tweedy Browne Global Value Adds to Stake in GlaxoSmithKline

    GuruFocus
  47. Liquidia Technologies And GlaxoSmithKline Advance Existing Collaboration; ...

    Benzinga
  48. 3 Big Drugs Likely To Hit The Market Soon

    IBD
  49. Regulatory Update: GSK and Theravance Announce Intention to File ...

    GuruFocus
  50. Guru Stocks at 52-Week Lows: RDS.A, PTR, UL, BP, GSK

    GuruFocus
  51. Five Prime Therapeutics Announces Initial Data From Ongoing Phase ...

    Benzinga
  52. GSK and Theravance Announce Results From the SUMMIT COPD CV Survival ...

    GuruFocus
  53. UPDATE: GlaxoSmithKline Says Tianjin Explosion Strained Supply ...

    Benzinga
  54. GlasxoSmithKlien Says It Holds Sales Rights To Tenozet In Japan/China ...

    Benzinga
  55. Five Prime Therapeutics Announces Oral Presentation of Initial ...

    Benzinga
  56. Dodge & Cox Acquires Stake in Priceline

    GuruFocus
  57. AptarGroup: The Leader in Dispensing Innovation

    GuruFocus
  58. US Stock Futures Slide Ahead Of Deere, Foot Locker Earnings

    Benzinga
  59. Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop ...

    Benzinga
  60. GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment ...

    GuruFocus
  61. Gilead Q2 Earnings Soar As HCV Shines, HIV Rebounds

    IBD
  62. Week Ahead: FOMC Meeting, GDP and More Earnings

    FoxBusiness
  63. Novartis' Mixed Q2: Sandoz Booms, Alcon Struggles

    IBD
  64. It's Not Too Late To Buy Gilead Sciences

    GuruFocus
  65. Benzinga's Volume Movers

    Benzinga
  66. Can Hepatitis B Be A Blockbuster Bug?

    IBD
  67. BioMarin, Sarepta Muscular Dystrophy Drugs Progress

    IBD
  68. Biotech IPOs Steam Ahead Despite Fears Of Overload

    IBD
  69. 5 NYSE Healthcare Stocks With The Highest ROE

    Benzinga
  70. Jim Cramer Advises His Viewers On GlaxoSmithKline, American International ...

    Benzinga
  71. Billionaire George Soros Ups Two Stakes in First Quarter

    GuruFocus
  72. Weekly 3-Year Low Highlights: GSK, TRP, NOV, CHK

    GuruFocus
  73. Guru Stocks at 52-Week Lows: XOM, WMT, PG, CVX, GSK

    GuruFocus
  74. Axovant IPO Best In 20 Years

    IBD
  75. Axovant Sciences Sets 20-Year Record For Biotech IPOs

    IBD
  76. Isis, Biogen Rare-Disease Drug Aids Infant Survival

    IBD
  77. Will GlaxoSmithKline Cut Its 6% Dividend?

    GuruFocus
  78. Perrigo buys Glaxo OTC drugs

    IBD
  79. Will Perrigo's Glaxo Buy Make It Too Pricey?

    IBD
  80. Big Pharma Companies Are Betting On Regenerative Medicine - Should ...

    GuruFocus
  81. Analyst Says GlaxoSmithKline Acquisition Will Benefit Pfizer

    GuruFocus
  82. 9 International Dividend Dogs With Upside Potential

    GuruFocus
  83. Endo International Acquires Par Pharmaceuticals For $8 Billion

    GuruFocus
  84. Tweedy Browne's Stocks With High Growing Yield

    GuruFocus
  85. Kahn Brothers Ups Investment in 4 Stocks

    GuruFocus
  86. Glaxo more bullish than Q1

    IBD
  87. IPO Stock Watch: Adaptimmune Upsizes But Stock Slips

    IBD
  88. Glaxo Q1 Earnings Miss, But 5-Year Guidance Strong

    IBD
  89. Isis Pharma Up As Bayer Licenses Thrombosis Drug

    IBD
  90. GlaxoSmithKline

    IBD
  91. Novartis EPS beats the Street

    IBD
  92. Taking a Closer Look at GlaxoSmithKline

    GuruFocus
  93. Jefferies Names AbbVie As Top Pharmaceutical Pick, Offers Alternative ...

    Benzinga
  94. New Potential HIV Vaccine Drug 'Absolutely 100% Effective' In ...

    Benzinga
  95. Dodge & Cox 2014 Equity Year in Review

    GuruFocus
  96. Why Muscular Dystrophy Is Biotech's Favorite Orphan

    IBD
  97. Making Money With Charles Payne: 02/13/15

    FoxBusiness
  98. Simons-Founded Renaissance Technologies Buys Apple, Closes Facebook, ...

    Benzinga
  99. Stocks Edge Higher Friday; Glaxo, Taiwan Semi Muscle Up

    IBD
  100. Bestinfond's Top 5 New Buys During Q4

    GuruFocus
Trading Center